Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
NCT06844864 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2025-04-30
Summary
Enquire involvement of trained immunity in the pathogenesis of IgG4RD
Conditions
- IgG4 Related Disease
Sponsors & Collaborators
-
IRCCS San Raffaele
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-03-01
- Primary Completion
- 2025-09-30
- Completion
- 2025-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
NCT06169150 ·Status: RECRUITING
-
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
NCT06941584 ·Status: RECRUITING
-
IgG-4 Levels in Systemic Sclerosis
NCT04219592 ·Status: COMPLETED
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Belimumab Treatment for IgG4-related Disease
NCT04660565 ·Status: UNKNOWN ·Phase: PHASE4
-
Markers of Favorable Response to FcRn Inhibitors(INFORM)
NCT06685055 ·Status: RECRUITING
-
To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
NCT03368274 ·Status: UNKNOWN ·Phase: PHASE4
-
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
NCT04388072 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 ·Status: UNKNOWN ·Phase: NA
-
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
NCT00538915 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of IMO-8400 in Adult Patients With Dermatomyositis
NCT02612857 ·Status: COMPLETED ·Phase: PHASE2
-
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04881682 ·Status: RECRUITING ·Phase: PHASE2
-
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
NCT06723548 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
NCT00661401 ·Status: COMPLETED ·Phase: NA
-
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
NCT06909253 ·Status: RECRUITING
-
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
NCT03330418 ·Status: TERMINATED ·Phase: PHASE3
-
The Role of the Thymus in Myasthenia Gravis
NCT01102192 ·Status: COMPLETED
-
Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
NCT00348296 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarkers in Autoimmune Disease of Nervous System
NCT06502015 ·Status: RECRUITING
-
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
NCT02115997 ·Status: COMPLETED ·Phase: PHASE4
-
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
NCT01813617 ·Status: COMPLETED
-
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
NCT05357781 ·Status: RECRUITING
-
Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
NCT01287689 ·Status: COMPLETED